The Effect of Epidural Steroid Use in Patients With Continous Epidural Block in PHN Patients.

NCT ID: NCT03995563

Last Updated: 2019-06-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-05-15

Study Completion Date

2020-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The efficiency of epidural steroid injection in patients who has postherpetic neuralgia is well known. In this study, the purpose is whether the continous epidural steroid injection is effective or not.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Continous epidural injection will be done during 10 days. D group will be injected a 0.19% ropivacaine 8mL and dexametasone 1mg every other day during 10 days.

Continous epidural injection will be done during 10 days N group will be injected a 0.19% ropivacaine 8mL only every other day during 10 days

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neuralgia,Postherpetic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

D group

0.19% Ropivacaine 8mL + Dexametasone 1mg every other day injection during 10 days

Group Type ACTIVE_COMPARATOR

Dexamethasone

Intervention Type DRUG

Continous epidural injection will be done during 10 days. D group will be injected a 0.19% ropivacaine 8mL and dexametasone 1mg every other day during 10 days.

.

Ropivacaine

Intervention Type DRUG

Continous epidural injection will be done during 10 days Both group will be injected a 0.19% ropivacaine 8mL every other day during 10 days

N group

0.19% Ropivacaine 8mL only every other day injection during 10 days

Group Type PLACEBO_COMPARATOR

Ropivacaine

Intervention Type DRUG

Continous epidural injection will be done during 10 days Both group will be injected a 0.19% ropivacaine 8mL every other day during 10 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dexamethasone

Continous epidural injection will be done during 10 days. D group will be injected a 0.19% ropivacaine 8mL and dexametasone 1mg every other day during 10 days.

.

Intervention Type DRUG

Ropivacaine

Continous epidural injection will be done during 10 days Both group will be injected a 0.19% ropivacaine 8mL every other day during 10 days

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

DEXA-S Rocaine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who has herpes zoster
* Patients has a period (at least 1month) after onset of herpes zoster
* Patients has a definite symptom along dermatome
* ASA class I - II
* Age : 18 - 80 years

Exclusion Criteria

* Patients who has a cancer
* Patients who has a neurologic, psychologic, renal, hepatic and hematologic disease
* Patients who has a other dermatologic disease
* Patients who has major operation \& procedure history
* Patients who has a other pain origin
* Patients who can not be inserted epidural catheter
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Korea University Guro Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jung Eun Kim

Assistant professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kangnam sacred heart hospital

Seoul, Yeongdeungpo-gu, South Korea

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jung Eun Kim, MD, PhD

Role: CONTACT

+82-10-7271-5391

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jung Eun Kim, MD, PhD

Role: primary

+82-10-7271-5391

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2019-04-011

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.